Stocktoria
BeOne Medicines Ltd. ONC
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2016-03-02
BeOne Medicines Ltd. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.3B | $3.8B | $2.5B | $1.4B | $1.2B | $308.9M | $428.2M | $198.2M | $238.4M | $1.1M |
| Gross profit | $4.7B | $3.2B | $2.1B | $1.1B | $1.0B | — | — | — | — | — |
| R&D expense | $2.1B | $2.0B | $1.8B | $1.6B | $1.5B | $1.3B | $927.3M | $679.0M | $269.0M | $98.0M |
| SG&A expense | $2.1B | $1.8B | $1.5B | $1.3B | $990.1M | $600.2M | $388.2M | $195.4M | $62.6M | $20.1M |
| Operating income | $447.1M | -$568.2M | -$1.2B | -$1.8B | -$1.4B | -$1.7B | -$959.9M | -$705.8M | -$98.5M | -$117.1M |
| Income tax | $129.9M | $111.8M | $55.9M | $42.8M | $19.2M | $10.4M | $7.0M | -$15.8M | $2.2M | $54,000 |
| Net income | $286.9M | -$644.8M | -$881.7M | -$2.0B | -$1.5B | -$1.6B | -$948.6M | -$673.8M | -$93.1M | -$119.2M |
| EPS (diluted) | $0.19 | $-0.47 | $-0.65 | $-1.49 | $-1.21 | $-1.50 | $-1.22 | — | — | — |
| Operating cash flow | $1.1B | -$140.6M | -$1.2B | -$1.5B | -$1.3B | -$1.3B | -$750.3M | -$547.7M | $12.8M | -$89.5M |
| Free cash flow | $941.7M | -$633.3M | -$1.7B | -$1.8B | -$1.6B | -$1.4B | -$839.9M | -$618.0M | -$33.6M | -$113.0M |
| Cash & equivalents | $4.5B | $2.6B | $3.2B | $3.9B | $4.4B | $1.4B | $618.0M | $712.9M | $239.6M | $87.5M |
| Inventory | $608.2M | $495.0M | $416.1M | $282.3M | $242.6M | $89.3M | $28.6M | $16.2M | $10.9M | — |
| Total assets | $8.2B | $5.9B | $5.8B | $6.4B | $8.5B | $5.6B | $1.6B | $2.2B | $1.0B | $405.8M |
| Total liabilities | $3.8B | $2.6B | $2.3B | $2.0B | $2.4B | $1.7B | $633.9M | $496.0M | $362.2M | $52.9M |
| Shareholders' equity | $4.4B | $3.3B | $3.5B | $4.4B | $6.1B | $3.9B | $962.2M | $1.8B | $684.2M | $352.9M |
Growth · year-over-year · Revenue CAGR 157.6%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +40.2% | +55.0% | +73.7% | +20.4% | +280.8% | -27.9% | +116.0% | -16.8% | +22179.2% | -87.9% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.